As of 2026-05-05, the Relative Valuation of Verrica Pharmaceuticals Inc (VRCA) is (19.42) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.27 USD, the upside of Verrica Pharmaceuticals Inc based on Relative Valuation is -409.7%.
The range of the Relative Valuation is (19.01) - (19.49) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.3x - 24.7x | 19.3x |
| Forward P/E multiples | 17.0x - 18.7x | 18.0x |
| Fair Price | (19.01) - (19.49) | (19.42) |
| Upside | -403.2% - -410.8% | -409.7% |
| Date | P/E |
| 2026-05-01 | -6.02 |
| 2026-04-30 | -6.12 |
| 2026-04-29 | -6.32 |
| 2026-04-28 | -6.27 |
| 2026-04-27 | -6.56 |
| 2026-04-24 | -6.70 |
| 2026-04-23 | -6.23 |
| 2026-04-22 | -6.25 |
| 2026-04-21 | -6.07 |
| 2026-04-20 | -6.13 |
| 2026-04-17 | -6.07 |
| 2026-04-16 | -5.96 |
| 2026-04-15 | -5.68 |
| 2026-04-14 | -5.49 |
| 2026-04-13 | -5.40 |
| 2026-04-10 | -4.91 |
| 2026-04-09 | -5.60 |
| 2026-04-08 | -5.59 |
| 2026-04-07 | -5.59 |
| 2026-04-06 | -5.74 |
| 2026-04-02 | -5.25 |
| 2026-04-01 | -5.27 |
| 2026-03-31 | -5.08 |
| 2026-03-30 | -4.57 |
| 2026-03-27 | -4.21 |
| 2026-03-26 | -4.22 |
| 2026-03-25 | -4.44 |
| 2026-03-24 | -4.30 |
| 2026-03-23 | -4.66 |
| 2026-03-20 | -5.23 |
| 2026-03-19 | -5.57 |
| 2026-03-18 | -5.48 |
| 2026-03-17 | -6.06 |
| 2026-03-16 | -5.93 |
| 2026-03-13 | -5.87 |
| 2026-03-12 | -5.91 |
| 2026-03-11 | -6.01 |
| 2026-03-10 | -5.74 |
| 2026-03-09 | -5.46 |
| 2026-03-06 | -5.10 |
| 2026-03-05 | -4.99 |
| 2026-03-04 | -5.12 |
| 2026-03-03 | -4.92 |
| 2026-03-02 | -5.16 |
| 2026-02-27 | -5.25 |
| 2026-02-26 | -5.25 |
| 2026-02-25 | -5.35 |
| 2026-02-24 | -5.37 |
| 2026-02-23 | -5.39 |
| 2026-02-20 | -5.56 |